| Summary: | Chronic obstructive pulmonary disease (COPD) is a global health
problem. It�s been proven that systemic inflammation in COPD contributes to the
development of intra and extra pulmonary disorders, and is an independent risk
factor for exaxerbation. The use of corticosteroids as anti-inflammatory agents has
limitation for their undesirable side effects and different efficacy among the
patients. Erdosteine, a mucolytic agent widely used in COPD, has been proven to
be able to inhibit several mediators such as reactive oxygen species (ROS) and
eicosanoids, which are involved in oxydative stress and inflammation. This study
is aimed to discover the effects of erdosteine administration in serum C-Reactive
Proteine (CRP) level in stable COPD patients.
This study is a double blind randomized controlled trial. Subjects are
stable COPD patients in Dr. Sardjito Hospital. They are divided into two different
groups, receiving 2 x 300 mg of erdosteine for 10 days and placebos. Evaluation
of CRP levels are held before treatment, on the sixth, and on the eleventh day,
using quantitative immunometric assay.
Results of the study are analyzed by computer program. Difference of
serum CRP level between the groups are analyzed using independent t test or
Mann Whitney U test. Multivariate analysis using linar regression analysis is
performed to determine the degree of relationship between independent variables
and outcome. It�s considered to be statistically significant if p <0.05 and
confidence interval of 95%.
|
|---|